NEO 7.7 (+6.06%)
US64049M2098Medical Diagnostics & ResearchDiagnostics & Research

NeoGenomics (NEO) Competitor Comparison

We are evaluating the key criteria listed to compare NeoGenomics (NEO) against its competitors in the Diagnostics & Research industry.

Performance 10 years - NEO ranking 26 / 58

These are the competitors of NeoGenomics in the industry Diagnostics & Research ranked by performance 10 years
1. Lantheus Holdings LNTH
1.66K
2. Heska HSKA
1.65K
3. Medpace Holdings MEDP
967.46
4. Natera NTRA
774.33
5. IDEXX Laboratories IDXX
623.03
6. RadNet RDNT
532.5
7. DexCom DXCM
373.57
8. Danaher DHR
255.1
9. PerkinElmer PKI
247.07
10. Mettler-Toledo MTD
238.24
11. Thermo Fisher Scientific TMO
234.74
12. Twist Bioscience TWST
201.85
13. CareDx CDNA
200
14. Waters WAT
175.23
15. Agilent Technologies A
159.76
16. Quest Diagnostics DGX
149.12
17. Laboratory Corp of America Holdings LH
142.89
18. IQVIA Holdings IQV
130.06
19. Fulgent Genetics FLGT
123.02
20. Exact Sciences EXAS
120.92
21. Icon ICLR
117.52
22. Syneos Health SYNH
113.83
23. Qiagen QGEN
70.88
24. Charles River Laboratories CRL
66.03
25. Meridian Bioscience VIVO
60.69
26. NeoGenomics NEO
59.75
27. Guardant Health GH
58.74
28. Ortho Clinical Diagnostics Holdings OCDX
13.74
29. Inotiv NOTV
5.73
30. National Research NRC
-13.72
31. Anixa Biosciences ANIX
-14.46
32. Olink Holding OLK
-26.82
33. Bioventus BVS
-51.39
34. Sotera Health SHC
-52.15
35. Illumina ILMN
-57.35
36. Exagen XGN
-64.17
37. Neogen NEOG
-64.27
38. Global Cord Blood CO
-66.57
39. DarioHealth DRIO
-75.47
40. Enzo Biochem ENZ
-77.8
41. Myriad Genetics MYGN
-77.98
42. Sera Prognostics SERA
-80.61
43. Pacific Biosciences of California PACB
-81.07
44. Personalis PSNL
-82.37
45. MaxCyte MXCT
-83.4
46. Co-Diagnostics CODX
-83.5
47. Psychemedics PMD
-85.71
48. MDxHealth MDXH
-85.84
49. bioAffinity Technologies BIAF
-88.45
50. Biodesix BDSX
-92.64
51. SeqLL SQL
-95.22
52. Prenetics Global PRE
-95.55
53. Neuronetics STIM
-97
54. Aspira Womens Health AWH
-97.44
55. Trinity Biotech TRIB
-98.9
56. Organovo Holdings ONVO
-99.26
57. Interpace Biosciences IDXG
-99.49
58. Precipio PRPO
-99.72

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.